Risk of breast cancer in carriers of BRCA gene mutations.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to V Grann.
Explore the source record for details and available documents.
Forty-four evaluable patients with non-small cell carcinoma of the lung were treated with cisplatin, cyclophosphamide, vincristine, and doxorubicin. The overall response rate was 57%. The 16% who had complete response had a median survival of 81 weeks.
A case of posttransfusion purpura was notable for the manner of antibody detection and response to therapy. The antibody failed to fix complement but was detected by platelet aggregometry studies and confirmed by the chromium 51 release assay. The course was unaffected by plasmapharesis.
A unique case of gamma3 heavy chain disease with two related serum proteins is reported. One molecule appears to be an IgG3lambda myeloma protein. The second molecule is a dimer of a shortened gamma3 heavy chain that has an unblocked amino terminus and lacks the VH and CH1 domains. Its probable origin as a synthetic product is discussed. The clinical and pathologic features of this patient resemble those of other patients with gamma heavy chain disease more than those of patients with multiple myeloma. It seems likely that the heavy chain disease protein is the result of a mutational event in the malignant clone originally producing the myeloma protein.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.